KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $120.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $120.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $120.8 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $120.8 million in Q4 2025 for Royalty Pharma, down from $502.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $502.9 million in Q3 2025 to a low of $900000.0 in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $65.0 million across 4 years, with a median of $11.8 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 80.55% in 2023 and later soared 8913.23% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.5 million in 2022, then crashed by 64.0% to $900000.0 in 2023, then skyrocketed by 520.0% to $5.6 million in 2024, then skyrocketed by 2065.65% to $120.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RPRX at $120.8 million in Q4 2025, $502.9 million in Q3 2025, and $143.3 million in Q2 2025.